Pazenir 5 mg/ml powder for dispersion for infusion. clinical trials

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)​

This study looks at a new combination of treatments for advanced non-small cell lung cancer. It compares a new drug (MK-7684A) plus chemotherapy to an existing drug (pembrolizumab) plus chemotherapy, to see which works better and is safer.